Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease

Filing Supported by Positive Results from Two Pivotal Phase 3 Efficacy Studies and One 12-Month Phase 3 Safety Study DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Nov. 13, 2017 -- (Healthcare Sales & Marketing Network) -- Theravance Biopharma, Inc.... Biopharmaceuticals, FDA Theravance Biopharma, Mylan, Revefenacin, Chronic Obstructive Pulmonary Disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news